Vivek Subbiah

143PUBLICATIONS
529CO-AUTHORS
Molecular targetsTumour immunologyGene and molecular therapyPredictive and prognostic markersOncology and carcinogenesis not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (143)

|Aug 11, 2026
ERK1/2 Inhibitor Ulixertinib in Pan-cancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L.

|Jul 31, 2026
The weight of the enemy: Tumor burden as a tumor-agnostic prognostic marker and the limits of immunotherapy.

|Jul 11, 2026
Personalized Radionuclide Therapy via Avidin-Biotin Pretargeting: Biodistribution and Dosimetry of 177Lu-DOTA-biotin with AvidinOX™ in Solid Tumors.

|Jun 01, 2026
Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation.

|May 27, 2026
Should We Call Every Cancer a Rare Cancer?

|Apr 03, 2026
Living Guidelines for Tumor-Agnostic Therapies: A Pathway to Next-Generation Cancer Treatment.

Vivek Subbiah, Thomas K Oliver, Jim Palma

Pageof 24

Frequent Collaborators

15 joint publications

Aung Naing

14 joint publications

Jason Roszik

14 joint publications

David S Hong

13 joint publications

Razelle Kurzrock